Specific allergen immunotherapy: Effect on immunologic markers and clinical parameters in asthmatic children

Journal of Investigational Allergology and Clinical Immunology

Volumn 17, Issue 5, 2007, Pages 286-291

  Cevit, Omer ^a   Kendirli, S G ^b   Yilmaz, M ^b   Altintas, D U ^b   Karakoc, G B ^c  

^a CUMHURIYET UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^c NONE

Author keywords

Asthma; Childhood; House dust mite; Specific allergen immunotherapy

Indexed keywords

ALLERGEN; CORTICOSTEROID; IMMUNOGLOBULIN E; MONOCYTE CHEMOTACTIC PROTEIN; NITRIC OXIDE; SALBUTAMOL;

ADOLESCENT; ALLERGY; ARTICLE; ASTHMA; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DERMATOPHAGOIDES; DERMATOPHAGOIDES PTERONYSSINUS; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; LUNG FUNCTION; MALE; PRICK TEST; PROTEIN EXPRESSION; PROVOCATION TEST;

ADOLESCENT; ANTIGENS, DERMATOPHAGOIDES; ASTHMA; BIOLOGICAL MARKERS; BRONCHIAL PROVOCATION TESTS; CHEMOKINE CCL2; CHILD; DESENSITIZATION, IMMUNOLOGIC; EOSINOPHIL CATIONIC PROTEIN; FEMALE; HUMANS; MALE; NITRIC OXIDE; TREATMENT OUTCOME;

EID: 35548962427     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Bousquet J, Lockey R, Malling H. WHO position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy. 1998;44 (Suppl 1):2-42.
2. Abramson M, Puy R, Weiner J. Immunotherapy in asthma: an updated systematic review. Allergy. 1999;54:1022-41.
3. Wahn U. Immunotherapy in children. Curr Opin Allergy Clin Immunol. 2002;2:557-60.
4. Hedlin G, Wille S, Browaldh L, Hildebrand H, Holmgren D, Lindfors A, Nordvall SL, Lowenstein H. Immunotherapy in children with allergic asthma: effect on bronchial hyperreactivity and pharmacotherapy. J Allergy Clin Immunol. 1999;103:609-14.
5. Gruber W, Eber E, Mileder P, Modl M, Weinhandl E, Zach MS. Effect of specific immunotherapy with house dust mite extract on the bronchial responsiveness of pediatric patients. Clin Exp Allergy. 1999;29:176-81.
6. Pifferi M, Baldini G. Marrazzini G, Baldini M, Ragazzo V, Pietrobelli A, Boner AL. Benefits of immunotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: a three-year prospective study. Allergy. 2002;57:785-90.
7. Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, Koivikko A, Koller DY, Niggemann B, Norberg LA, Urbanek R, Valovirta E, Wahn U. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-Study). J Allergy Clin Immunol. 2002;109:251-6.
8. Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol. 1997;9:450-3.
9. Arvidsson MB, Lowhagen O, Rak S. Allergen specific immunotherapy attenuates early and late phase reactions in lower airways of birch pollen asthmatic patients: a double blind placebo-controlled study. Allergy. 2004;59:74-80.
10. Akdis CA, Akdis M, Blesken T, Wymann D, Alkan SS, Muller U, Blaser K. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest.1996;98:1676-83.
11. Hamid QA, Schotman E, Jacobson MR, Walker SM, Durham SR. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol. 1997;99:254-60.
12. Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, Kay AB, Hamid QA. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol. 1996;97:1356-65.
13. Venge P. Soluble markers of allergic inflammation. Allergy. 1994:49:1-8.
14. Secrist H, DeKruyff RH, Umetsu DT. Interleukin-4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type. J Exp Med. 1995;181:1081-9.
15. Barnes PJ, Liew FY. Nitric oxide and asthmatic inflammation. Immunol Today. 1995;16:128-30.
16. Ricciardolo FLM. Multiple roles of nitric oxide in the airways. Thorax. 2003;58:175-82.
17. Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne E, Barnes PJ. Increased nitric oxide in exhaled air of asthmatic patients. Lancet. 1994;343:133-5
18. Massaro AF, Mehta S, Lilly CM, Kobzik L, Reilly JJ, Drazen JM. Elevated nitric oxide concentrations in isolated lower airway gas of asthmatic subjects. Am J Respir Crit Care Med. 1996;153:1510-4.
19. Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, Venge P, Ahlstedt S, Simony-Lafontaine J, Godard P. Eosinophilic inflammation in asthma. N Engl J Med. 1990:323:1033-9.
20. Arvidsson MB, Lowhagen O, Rak S. Allergen specific immunotherapy attenuates early and late phase reactions in lower airways of birch pollen asthmatic patients: a double blind placebo-controlled study. Allergy. 2004;59:74-80.
21. Ohashi Y, Nakai Y, Kakinoki Y, Ohno Y, Sakamoto H, Kato A, Tanaka A. Effect of immunotherapy on serum levels of eosinophil cationic protein in perennial allergic rhinitis. Ann Otol Rhinol Laryngol. 1997;106:848-53.
22. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. Monocyte- chemoattractant protein 1 acts as a T lymphocyte. Proc Natl Acad Sci USA 1994;91:3652-6.
23. Kuna P, Reddigari SR, Schall TJ, Rucinski D, Sadick M, Kaplan AP. Characterization of the human basophil response to cytokines, growth factors, and histamine releasing factors of the intercrinechemokine family. J Immunol. 1993;150:1932-43.
24. GINA. Global strategy for asthma management and prevention. NHLBI/WHO workshop report. NHLBI publication, 1995.
25. Bousquet J, Guerin B, Dotte A, Dhivert H, Djoukhadar F, Hewitt B, Michel FB. Comparison between rush immunotherapy with a standardized allergen and an alum adjuved pyridine extracted material in grass pollen allergy. Clin Allergy.1985;15:179-93.
26. Holgate ST, Bodey KS, Janezic A, Frew AJ, Kaplan AP, Teran LM. Release of RANTES, MIP-1α, and MCP-1 into asthmatic airways following endobronchial allergen challenge. Am J Respir Crit Care Med. 1997;156:1377-83.
27. Rose CE, Sung SS, Fu SM. Significant involvement of CCL2 (MCP-1) in inflammatory disorders of the lung. Microcirculation. 2003;10:273-88.
28. Kaburagi Y, Shimada Y, Nagaoka T, Hasegawa M, Takehara K, Sato S. Enhanced production of CC-chemokines (RANTES, MCP-1, MIP-1α, MIP-1β, and eotaxin) in patients with atopic dermatitis. Arch Dermatol Res. 2001;293:350-5.
29. Kuna R, Lazarovich M, Kaplan AP. Chemokines in seasonal allergic rhinitis. J Allergy Clin Immunol. 1996;97:104-12.
30. Gonzalo JA, Llyod CM, Wen D, Albar JP, Wells TN, Proudfoot A. The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyper-responsiveness. J Exp Med. 1998;188:157-67.
31. de Arruda-Chaves E, De Conti D, Tebaldi T. Nitric oxide sera levels as an inflammatory marker in asthma. J Investig Allergol Clin Immunol. 2002;12(2):120-3.
32. Hung CH, Lee MY, Tsai YG, Cheng SN, Yang KD. Hyposensitization therapy reduced exhaled nitric oxide in asthmatic children with corticosteroid dependency. Acta Paediatr Taiwan. 2004;45:89-93.
33. Inci D, Altintas DU, Kendirli SG, Yilmaz M, Karakoc GB. The effect of specific immunotherapy on exhaled breath condensate nitrite levels. Allergy. 2006;61:899-900
34. Wang H, Lin X, Hao C, Zhang C, Sun B, Zheng J, Chen P, Sheng J, Wu A, Zhong N. A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients. Allergy. 2006;61:191-7.